2012
DOI: 10.1159/000345508
|View full text |Cite
|
Sign up to set email alerts
|

Circulating Angiotensin-Converting Enzyme 2 Activity in Kidney Transplantation: A Longitudinal Pilot Study

Abstract: Background/Aims: Angiotensin-converting enzyme 2 (ACE2) is the only known active homologue of ACE, and degrades angiotensin (Ang) II and Ang I to Ang(1–7) and Ang(1–9), respectively. The role of ACE2 in kidney transplant (KT) is unknown. Our objective was to investigate circulating ACE2 activity in KT patients, and the relationship between serum ACE2 activity and age, gender, graft function and cardiovascular risk markers in KT patients. Methods: 113 KT patients with stable graft function were included in this… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
36
1

Year Published

2013
2013
2019
2019

Publication Types

Select...
7
2

Relationship

5
4

Authors

Journals

citations
Cited by 28 publications
(41 citation statements)
references
References 51 publications
(58 reference statements)
4
36
1
Order By: Relevance
“…ACE2 enzymatic activity assay was performed as previously published by our group [25,44,45,46] and adapted to different tissues. Briefly, 5 μL of serum or 5 μg of tissue samples that were previously homogenized were incubated using a 100 mM Tris-HCl, 600 mM NaCl, 10 μM ZnCl 2 , pH 7.5 buffer in the presence of protease inhibitors containing 100 μM captopril, 5 μM amastatin, 5 μM bestatin (all from Sigma-Aldrich, Madrid, Spain), and 10 μM Z-Pro-prolinal (Enzo Life Sciences, Grupo Taper, Madrid, Spain).…”
Section: Methodsmentioning
confidence: 99%
“…ACE2 enzymatic activity assay was performed as previously published by our group [25,44,45,46] and adapted to different tissues. Briefly, 5 μL of serum or 5 μg of tissue samples that were previously homogenized were incubated using a 100 mM Tris-HCl, 600 mM NaCl, 10 μM ZnCl 2 , pH 7.5 buffer in the presence of protease inhibitors containing 100 μM captopril, 5 μM amastatin, 5 μM bestatin (all from Sigma-Aldrich, Madrid, Spain), and 10 μM Z-Pro-prolinal (Enzo Life Sciences, Grupo Taper, Madrid, Spain).…”
Section: Methodsmentioning
confidence: 99%
“…The ACE2 fluorescent enzymatic assay protocol was performed as previously described with modifications, using an ACE2 quenched fluorogenic substrate (Mca-Ala-Pro-Lys(Dnp)-OH, Enzo Life Sciences) [10], [11]. Briefly, 20 µL of serum was incubated with a buffer (100 mM Tris-HCl, 600 mM NaCl, 10 µM ZnCl 2 , pH 7.5) in the presence of protease inhibitors, including 100 µM captopril, 5 µM amastatin, 5 µM bestatin (all from Sigma-Aldrich), and 10 µM Z-Pro-prolinal (Enzo Life Sciences).…”
Section: Methodsmentioning
confidence: 99%
“…In addition, in a multivariate analysis, circulating ACE2 activity directly correlated with the classical cardiovascular risk factors, namely older age, diabetes, and male sex (7). Increased activity of circulating ACE2 has also been detected in males compared with females after kidney transplant (112) and in hemodialysis patients (99). Mizuiri et al did not find sexual dimorphism in urinary ACE2 activity or protein levels in patients with CKD (78).…”
Section: Sex Differences On Ras Regulatory Arms: Ace and Ace2mentioning
confidence: 98%